Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,609,936
  • Shares Outstanding, K 21,200
  • Annual Sales, $ 141,100 K
  • Annual Income, $ 12,560 K
  • 36-Month Beta 0.91
  • Price/Sales 25.70
  • Price/Cash Flow 45.37
  • Price/Book 9.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
154.51 +9.13%
on 04/06/18
172.07 -2.01%
on 04/18/18
+0.22 (+0.13%)
since 03/19/18
3-Month
145.67 +15.75%
on 02/09/18
184.79 -8.76%
on 03/13/18
+12.80 (+8.22%)
since 01/19/18
52-Week
103.75 +62.52%
on 04/21/17
184.79 -8.76%
on 03/13/18
+63.56 (+60.50%)
since 04/19/17

Most Recent Stories

More News
Calithera's Kidney Cancer Candidate Gets Fast Track Status

Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

LGND : 168.60 (-0.99%)
EXEL : 21.09 (-1.54%)
CALA : 6.45 (+4.03%)
BMY : 51.61 (-1.32%)
Bayer to Divest 3.6% Stake to Singapore Company Temasek

Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.

PTGX : 8.75 (-1.91%)
BAYRY : 30.7600 (-1.03%)
LGND : 168.60 (-0.99%)
MON : 124.60 (-0.28%)
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline

The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.

AGIO : 88.29 (+0.30%)
CELG : 89.62 (-1.53%)
LGND : 168.60 (-0.99%)
INFI : 2.20 (+0.46%)
Alnylam (ALNY) Reports Positive Data for RNAi Candidate

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

PTGX : 8.75 (-1.91%)
LGND : 168.60 (-0.99%)
CATB : 1.72 (-4.97%)
ALNY : 96.19 (-1.55%)
Alkermes Rallies as FDA Accepts NDA for Depression Drug

Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.

PTGX : 8.75 (-1.91%)
LGND : 168.60 (-0.99%)
CATB : 1.72 (-4.97%)
ALKS : 46.15 (-1.49%)
Merck's Keytruda Betters Survival in Lung Cancer Combo Study

Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.

LGND : 168.60 (-0.99%)
MRK : 58.64 (-0.48%)
LLY : 79.75 (+0.04%)
BMY : 51.61 (-1.32%)
Intercept Reports Phase III Sub-Study Liver Biopsy Data

Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary...

PTGX : 8.75 (-1.91%)
LGND : 168.60 (-0.99%)
CATB : 1.72 (-4.97%)
ICPT : 69.23 (-3.82%)
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

LGND : 168.60 (-0.99%)
NVS : 79.00 (-3.30%)
RIGL : 4.06 (+4.64%)
GSK : 39.88 (-1.38%)
Verastem (VSTM) in Focus: Stock Moves 8% Higher

Shares of Verastem (VSTM) rose nearly 8% yesterday.

LGND : 168.60 (-0.99%)
VSTM : 4.15 (+0.24%)
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy

Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.

PTGX : 8.75 (-1.91%)
LGND : 168.60 (-0.99%)
CATB : 1.72 (-4.97%)
BLCM : 7.54 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 174.37
1st Resistance Point 172.32
Last Price 168.60
1st Support Level 167.98
2nd Support Level 165.69

See More

52-Week High 184.79
Last Price 168.60
Fibonacci 61.8% 153.83
Fibonacci 50% 144.27
Fibonacci 38.2% 134.71
52-Week Low 103.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar